Rola Hamood1, Hatem Hamood2, Ilya Merhasin3, Lital Keinan-Boker4. 1. School of Public Health, University of Haifa, Haifa, Israel. 2. School of Public Health, University of Haifa, Haifa, Israel; Leumit Health Services, Karmiel, Israel. Electronic address: hhamood@leumit.co.il. 3. Leumit Health Services, Netanya, Israel. 4. School of Public Health, University of Haifa, Haifa, Israel; Ministry of Health, Israel Center for Disease Control, Ramat Gan, Israel.
Abstract
BACKGROUND: The current investigation examined the association between chemotherapy and/or radiotherapy and subsequent risk of cardiovascular disease (CVD) in breast cancer survivors. METHODS: A case-cohort study was conducted, based on 2165 female breast cancer survivors recruited from "Leumit" healthcare fund, who were diagnosed with primary nonmetastatic invasive breast cancer between 2002 and 2012. A 20% random subcohort was sampled at baseline, and all CVD cases were identified. Adjusted hazard ratios (HRs) with 95% confidence intervals (CI) were estimated by weighted Cox proportional hazards models. RESULTS: Of 2165 breast cancer survivors, 466 developed CVD over a mean follow-up of 5.7 years. The crude cumulative incidence of CVD accounting for death as a competing risk was 33.6% (95% CI, 29.6-37.6%) at 13 years of follow-up. Lifestyle components, collected post-CVD incidence, indicated a higher prevalence of poor nutrition and physical inactivity in CVD patients. In multivariable analyses, CVD was positively associated with radiotherapy without chemotherapy compared to no radiotherapy or chemotherapy (HR, 2.94; 95% CI, 1.17-7.38; p=.022), outpatient visits (HR per average 10-annual visits, 1.86; 95% CI, 1.50-2.31; p<.001), employment transition between breast cancer diagnosis and treatment: job loss versus no change (HR, 29.62; 95% CI, 12.72-68.97; p<.001), and inversely associated with education (HR per 1-year increment, 0.84; 95% CI, 0.75-0.94; p=.003). CONCLUSIONS: Radiotherapy administered as an adjuvant treatment for breast cancer elevates the risk of CVD. Preventive strategies should be directed to surveillance for radiotherapy-related CVD dysfunction. Efforts should also address lifestyle modifications and occupational rehabilitation in patients at a high risk of CVD.
BACKGROUND: The current investigation examined the association between chemotherapy and/or radiotherapy and subsequent risk of cardiovascular disease (CVD) in breast cancer survivors. METHODS: A case-cohort study was conducted, based on 2165 female breast cancer survivors recruited from "Leumit" healthcare fund, who were diagnosed with primary nonmetastatic invasive breast cancer between 2002 and 2012. A 20% random subcohort was sampled at baseline, and all CVD cases were identified. Adjusted hazard ratios (HRs) with 95% confidence intervals (CI) were estimated by weighted Cox proportional hazards models. RESULTS: Of 2165 breast cancer survivors, 466 developed CVD over a mean follow-up of 5.7 years. The crude cumulative incidence of CVD accounting for death as a competing risk was 33.6% (95% CI, 29.6-37.6%) at 13 years of follow-up. Lifestyle components, collected post-CVD incidence, indicated a higher prevalence of poor nutrition and physical inactivity in CVD patients. In multivariable analyses, CVD was positively associated with radiotherapy without chemotherapy compared to no radiotherapy or chemotherapy (HR, 2.94; 95% CI, 1.17-7.38; p=.022), outpatient visits (HR per average 10-annual visits, 1.86; 95% CI, 1.50-2.31; p<.001), employment transition between breast cancer diagnosis and treatment: job loss versus no change (HR, 29.62; 95% CI, 12.72-68.97; p<.001), and inversely associated with education (HR per 1-year increment, 0.84; 95% CI, 0.75-0.94; p=.003). CONCLUSIONS: Radiotherapy administered as an adjuvant treatment for breast cancer elevates the risk of CVD. Preventive strategies should be directed to surveillance for radiotherapy-related CVD dysfunction. Efforts should also address lifestyle modifications and occupational rehabilitation in patients at a high risk of CVD.
Authors: Heather Greenlee; Carlos Iribarren; Jamal S Rana; Richard Cheng; Mai Nguyen-Huynh; Eileen Rillamas-Sun; Zaixing Shi; Cecile A Laurent; Valerie S Lee; Janise M Roh; Margarita Santiago-Torres; Hanjie Shen; Dawn L Hershman; Lawrence H Kushi; Romain Neugebauer; Marilyn L Kwan Journal: J Clin Oncol Date: 2022-04-06 Impact factor: 50.717
Authors: Lathan Liou; Stephen Kaptoge; Joe Dennis; Mitul Shah; Jonathan Tyrer; Michael Inouye; Douglas F Easton; Paul D P Pharoah Journal: Breast Cancer Res Date: 2021-09-30 Impact factor: 6.466